SINGAPORE, SG / ACCESS Newswire / November 13, 2026 / Bayer raises its full-year earnings guidance after third-quarter pharmaceutical sales climb 8% to $5.2 billion, sending its shares more than 5% higher on the day of the release. The gain extends a rally that has taken the stock close to double its level of a year earlier. Kinzey Capital Management Pte. Ltd. traces most of the upgrade to pharmaceuticals rather than cost reductions, even as impairments and special charges produce a quarterly net loss.
The revised forecast lifts both ends of the full-year range for group EBITDA before special items by $222 million, to between $10.9 billion and $11.4 billion on a currency-adjusted basis. Free cash flow guidance improves by $1.1 billion to a full-year outflow of between $555 million and $1.7 billion. The year-end range for net financial debt falls by the same amount, to between $31.1 billion and $32.2 billion.
The pharmaceutical recovery rests on newer therapies that now outpace the revenue drag from older medicines exposed to generic competition. In the third quarter, the prostate cancer therapy Nubeqa grows 58.3% on a currency- and portfolio-adjusted basis, reaching close to $1.1 billion, while Kerendia, for kidney disease and heart failure, advances 64.9% on the same basis and tops $1.1 billion in sales over the latest four quarters. Eylea and Xarelto fall 23.5% and 30.7% on a currency-adjusted basis in the quarter as patent expiries expose both to generic rivals.
Profitability, not volume alone, explains the scale of the upgrade, with divisional EBITDA before special items climbing 23.6% to $1.4 billion in the third quarter. The margin widens by 3.5 points to 27.6% over the same period, and Bayer raises its full-year divisional margin guidance to between 25% and 27%, from 23% to 25%. Chief Executive Bill Anderson cites Nubeqa and Kerendia as evidence that the division has reached a turning point.
In his capacity as Director of Private Clients at Kinzey Capital Management, David Nilson reads the rally as "a market recalculating what Bayer's pharmaceuticals business is worth now that the growth drivers have reached scale in the reported numbers, not a reaction to any single line item". That reaction follows confirmation that the recovery registers in group-level figures rather than in divisional ones alone. The firm continues to watch how the earnings beat and raised guidance feed through to Bayer's debt load and litigation burden.
Group EBITDA before special items rises 6.9% to $1.8 billion in the third quarter on sales of $11.2 billion, ahead of the $1.6 billion analysts expected. The net loss narrows to $745.9 million from $1.1 billion a year earlier yet far exceeds the $268.6 million consensus, as impairments of $340.8 million on Xofigo and $238.7 million on Claritin combine with net special charges of $451.8 million. Nilson points to that divergence as a measure of "how much of this quarter was shaped by one-off charges rather than underlying trading, and that distinction matters for anyone reading the headline figures in isolation".
Net operating cash flow falls to $700.4 million in the third quarter from $1.9 billion a year earlier. The decline reflects $1.2 billion in payments to resolve glyphosate and PCB litigation, up from $780.3 million in the comparable quarter. Free cash flow swings to a $325.2 million outflow from a $661.6 million inflow in the prior-year period, although it would stand at $919.1 million stripped of settlement payments.
A financing deal with Apollo and a pending Roundup settlement ease the near-term pressure on Bayer's balance sheet. Apollo's $3 billion purchase of a minority stake in the long-acting reversible contraceptive business, completed during the quarter, helps fund roughly $5 billion in litigation payouts expected for the full year. Monsanto's proposed nationwide class settlement would resolve current and future Roundup claims tied to non-Hodgkin lymphoma through up to $7,250 million in declining, capped annual payments over 21 years, subject to court approval. Anderson expects approval within weeks, which would leave far fewer of the roughly 65,000 claims Bayer faces in US courts outstanding.
The claims trace to Bayer's purchase of Monsanto for more than $60 billion eight years ago, an acquisition whose lawsuits now push litigation provisions and liabilities to $11.8 billion. The raised guidance, lower debt range and pending settlement point to a balance sheet in repair, provided court approval follows management's timetable. Kinzey Capital Management maintains that headline earnings and underlying cash generation warrant separate reading wherever one-off legal charges shape the reported result.
Kinzey Capital Management, on the Record
From Singapore, Kinzey Capital Management manages discretionary multi-asset portfolios for families, foundations, companies and private clients, treating equities, bonds, funds and cash as a single book. Each mandate is built around what the capital must achieve, how soon it could be needed and how much fluctuation it can absorb, with instruments chosen to fit.
Corporate Reserves, Growth Portfolios, Joint and Family Accounts, and Income and Withdrawals last as long as the obligation the capital serves, while Second-Opinion Reviews and Concentrated Shareholdings are one-off engagements around existing holdings. Reporting measures each portfolio against its assigned purpose.
Kinzey Capital Management Pte. Ltd. is registered under UEN 202105652G, and its website is https://kinzey.com. Chloe Lim fields media enquiries at c.lim@kinzey.com.
SOURCE: Kinzey Capital Management Pte. Ltd.
View the original press release on ACCESS Newswire